SMMT
Summit Therapeutics Inc
$
26.540
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
26.905
Open
26.780
VWAP
26.37
Vol
1.64M
Mkt Cap
19.71B
Low
25.810
Amount
43.23M
EV/EBITDA(TTM)
--
Total Shares
701.98M
EV
19.10B
EV/OCF(TTM)
--
P/S(TTM)
--
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.092
+3.3%
--
--
-0.101
+26.42%
--
--
-0.121
+51.52%
Estimates Revision
The market is revising No Change the revenue expectations for Summit Therapeutics Inc. (SMMT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -20.13%.
EPS Estimates for FY2025
Revise Downward
-5.48%
In Past 3 Month
Stock Price
Go Down
-20.13%
In Past 3 Month
12 Analyst Rating
33.31% Upside
Wall Street analysts forecast SMMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMMT is 35.38 USD with a low forecast of 30.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
1 Sell
Strong Buy
33.31% Upside
Current: 26.540
Low
30.00
Averages
35.38
High
44.00
33.31% Upside
Current: 26.540
Low
30.00
Averages
35.38
High
44.00
UBS
NULL -> Buy
initiated
$30
2025-06-30
Reason
UBS
Price Target
$30
2025-06-30
initiated
NULL -> Buy
Reason
UBS initiated coverage of Summit Therapeutics with a Buy rating and $30 price target. The firm believes Summit's lead program, ivonescimab, could become the new standard of care in front-line non-small cell lung cancer with a greater than $7B peak sales opportunity, or $11B unadjusted, while the stock is pricing in about $5B, the analyst tells investors.
Leerink
Underperform
initiated
$12
2025-06-11
Reason
Leerink
Price Target
$12
2025-06-11
initiated
Underperform
Reason
Leerink initiated coverage of Summit Therapeutics with an Underperform rating and $12 price target. Ivonescimab, Summit Therapeutics' VEGF-A/PD-1 bispecific, is a strong product and Summit leadership deserves credit for licensing ex-China rights to the bispecific from Akeso long before the clinical outcomes were clearly compelling, the firm says. However, Leerink does not believe Ivonescimab is the next Keytruda. For the firm, consensus estimates assume an unrealistic share of the current anti-PD(L)1 total addressable market, given the intense and heterogenous competitive landscape, and compared to the PD-(L)1 era, higher threshold for clinical success, regulatory approval, and uptake.
Clear Street
Bill Maughan
initiated
$33
2025-05-22
Reason
Clear Street
Bill Maughan
Price Target
$33
2025-05-22
initiated
Reason
Clear Street
initiated
$33
2025-05-21
Reason
Clear Street
Price Target
$33
2025-05-21
initiated
Reason
Clear Street initiated coverage of Summit Therapeutics with a Buy rating and $33 price target.
TD Cowen
Tyler Van Buren
Buy
initiated
2025-05-08
Reason
TD Cowen
Tyler Van Buren
Price Target
2025-05-08
initiated
Buy
Reason
Jefferies
Kelly Shi
Buy
upgrade
$31 -> $44
2025-04-25
Reason
Jefferies
Kelly Shi
Price Target
$31 -> $44
2025-04-25
upgrade
Buy
Reason
Jefferies analyst Kelly Shi raised the firm's price target on Summit Therapeutics to $44 from $31 and keeps a Buy rating on the shares. Ivonescimab gained approval in China for first-line platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer, the analyst tells investors in a research note, citing a posting on the National Medical Products Administration website. The firm remains "optimistic" and sees "skewed upside" for Summit shares on the HARMONi-2 study. In light of the HARMONi-6 topline data and H-2 approval, Jefferies increased its probability of success on the first-line NSCLC global trials of HARMONi-7 and HARMONi-3. Today's China approval news marks Ivonescimab's second win in NSCLC, a much larger indication than the first approval, the firm says.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Summit Therapeutics Inc (SMMT.O) is -62.16, compared to its 5-year average forward P/E of -16.02. For a more detailed relative valuation and DCF analysis to assess Summit Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-16.02
Current PE
-62.16
Overvalued PE
5.80
Undervalued PE
-37.83
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-11.88
Current EV/EBITDA
-55.73
Overvalued EV/EBITDA
9.04
Undervalued EV/EBITDA
-32.81
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
364.08
Current PS
1902.45
Overvalued PS
970.86
Undervalued PS
-242.69
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+56.92%
-66.85M
Operating Profit
FY2025Q1
YoY :
+44.72%
-62.91M
Net Income after Tax
FY2025Q1
YoY :
+50.00%
-0.09
EPS - Diluted
FY2025Q1
YoY :
+104.36%
-61.59M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
47.0K
Volume
Months
6-9
1
250.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SMMT News & Events
Events Timeline
2025-07-03 (ET)
2025-07-03
10:30:39
AstraZeneca discussing $15B partnership with Summit Therapeutics, Bloomberg says
2025-07-03
10:21:54
AstraZeneca discussing $15B partnership with Summit Therapeutics, Bloomberg says
2025-06-30 (ET)
2025-06-30
08:19:59
Revolution Medicines, Summit Therapeutics team to evaluate RAS inhibitors
Sign Up For More Events
Sign Up For More Events
News
9.0
07-21NASDAQ.COMPinnedThis Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich
7.0
07-22PRnewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
8.0
07-17NASDAQ.COMNotable Wednesday Option Activity: SMMT, PEP, ZM
Sign Up For More News
People Also Watch
CW
Curtiss-Wright Corp
474.480
USD
-1.16%
INCY
Incyte Corp
68.900
USD
+2.26%
MORN
Morningstar Inc
277.040
USD
-2.04%
FTI
TechnipFMC PLC
32.420
USD
+0.71%
UNM
Unum Group
80.480
USD
+0.89%
SFM
Sprouts Farmers Market Inc
164.480
USD
-1.04%
AU
Anglogold Ashanti PLC
51.930
USD
+2.59%
BSY
Bentley Systems Inc
58.180
USD
+0.48%
GFI
Gold Fields Ltd
25.790
USD
+1.38%
EWBC
East West Bancorp Inc
108.960
USD
+0.52%
FAQ
What is Summit Therapeutics Inc (SMMT) stock price today?
The current price of SMMT is 26.54 USD — it has increased 0.76 % in the last trading day.
What is Summit Therapeutics Inc (SMMT)'s business?
What is the price predicton of SMMT Stock?
What is Summit Therapeutics Inc (SMMT)'s revenue for the last quarter?
What is Summit Therapeutics Inc (SMMT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Summit Therapeutics Inc (SMMT)'s fundamentals?
How many employees does Summit Therapeutics Inc (SMMT). have?